These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice. Martin AE; Schober DA; Nikolayev A; Tolstikov VV; Anderson WH; Higgs RE; Kuo MS; Laksmanan A; Catlow JT; Li X; Felder CC; Witkin JM CNS Neurol Disord Drug Targets; 2017; 16(4):492-500. PubMed ID: 28294051 [TBL] [Abstract][Full Text] [Related]
4. The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions. Drevets WC; Bhattacharya A; Furey ML Adv Pharmacol; 2020; 89():357-386. PubMed ID: 32616213 [TBL] [Abstract][Full Text] [Related]
5. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Lauterbach EC Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777 [TBL] [Abstract][Full Text] [Related]
6. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM Expert Opin Drug Discov; 2022 Oct; 17(10):1131-1146. PubMed ID: 35934973 [TBL] [Abstract][Full Text] [Related]
12. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. Witkin JM; Overshiner C; Li X; Catlow JT; Wishart GN; Schober DA; Heinz BA; Nikolayev A; Tolstikov VV; Anderson WH; Higgs RE; Kuo MS; Felder CC J Pharmacol Exp Ther; 2014 Nov; 351(2):448-56. PubMed ID: 25187432 [TBL] [Abstract][Full Text] [Related]
13. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Drevets WC; Zarate CA; Furey ML Biol Psychiatry; 2013 Jun; 73(12):1156-63. PubMed ID: 23200525 [TBL] [Abstract][Full Text] [Related]
14. Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients. Janowsky DS Curr Psychiatry Rep; 2011 Dec; 13(6):443-5. PubMed ID: 21976067 [TBL] [Abstract][Full Text] [Related]
15. Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice. Singh P; Singh TG Indian J Pharmacol; 2015; 47(4):388-93. PubMed ID: 26288470 [TBL] [Abstract][Full Text] [Related]
16. Antimuscarinic and other receptor-blocking properties of antidepressants. Richelson E Mayo Clin Proc; 1983 Jan; 58(1):40-6. PubMed ID: 6130192 [TBL] [Abstract][Full Text] [Related]
17. mGlu2/3 receptor as a novel target for rapid acting antidepressants. Chaki S Adv Pharmacol; 2020; 89():289-309. PubMed ID: 32616210 [TBL] [Abstract][Full Text] [Related]
18. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960 [TBL] [Abstract][Full Text] [Related]
19. mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects. Witkin JM Pharmacol Biochem Behav; 2020 Mar; 190():172854. PubMed ID: 31954773 [TBL] [Abstract][Full Text] [Related]
20. The antidepressant effects of anticholinergic drugs. Howland RH J Psychosoc Nurs Ment Health Serv; 2009 Jun; 47(6):17-20. PubMed ID: 19585799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]